Status: Finalised
First registered on:
03/04/2014
Last updated on:
10/08/2017
1. Study identification
EU PAS Register NumberEUPAS6305
Official titleStrattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2014 Bi-annual assessment report
Study title acronym
Study typeObservational study
Brief description of the studyThe objective of this study is to describe atomoxetine (Strattera) utilization patterns for patients treated in Germany, United Kingdom (UK), Sweden, and the Netherlands
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
EU RMP category 3 (required)
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsIMS Health
Department/Research groupReal World Evidence Solutions
Organisation/affiliationIMS Health
Details of (Primary) lead investigator
Title Dr
Last name Nicole
First name Kellier
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
International study
Germany
Netherlands
Sweden
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed16/08/201316/08/2013
Start date of data collection01/01/201401/01/2014
Start date of data analysis01/01/201401/01/2014
Date of interim report, if expected
Date of final study report28/03/201409/04/2014
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesEli Lilly and Company100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Nicole
First name Kellier
Address line 1Lilly Corporate Center
Address line 2
Address line 3
CityIndianapolis
Postcode46285
CountryUnited States
Phone number (incl. country code)13172763631
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Dr
Last name Nicole
First name Kellier
Address line 1Lilly Corporate Center
Address line 2
Address line 3
CityIndianapolis
Postcode46285
CountryUnited States
Phone number (incl. country code)13172763631
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)N06BA09 (atomoxetine)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Preterm newborns
Term newborns (0-27 days)
Infants and toddlers (28 days - 23 months)
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
Other population
Renal impaired
Hepatic impaired
Immunocompromised
Pregnant women
9. Number of subjects
Estimated total number of subjects0
Additional information
All patients meeting inclusion criteria
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Data sources not registered with ENCePP
Longitudinal prescription data, Germany
Disease analyzer, United Kingdom
Sources of data
Administrative database, e.g. claims database
Routine primary care electronic patient registry
Exposure registry
Pharmacy dispensing records
11. Scope of the study
What is the scope of the study?
Drug utilisation study
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
The objective of this study is to describe atomoxetine (Strattera) utilization patterns for patients treated in Germany, United Kingdom (UK), Sweden, and the Netherlands
Are there primary outcomes?Yes
Patient exposures
Patient discontinuation and adherence
Descriptive statistics
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Drug utilisation study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
For each country, patient counts will be provided for the most recent 5 full calendar years, and the moving annual total (MAT) will be provided for midyear of the most recent year of available data, when appropriate.
Patient exposures including treatment duration, duration of exposure, daily average dose, and frequent comorbid diagnoses will be presented (where available).
Patient discontinuation and adherence will be described, including the percentage of patients reinitiating therapy and the percentage of patients remaining on therapy at monthly time intervals. This will include data on mean and median length of therapy as well as mean daily dose.
Descriptive statistics including frequencies and proportions of patient count and demographics such as age and gender will be provided as well as frequencies and proportions for population characteristics such as common comorbidities and concomitant medication.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
